FindTrial
Sign In

To compare low cost treatment regimen with standard treatment in patients with hepatorenal syndrome

A randomized controlled trial of terlipressin and albumin versus albumin, low dose dopamine and frusemide in hepatorenal syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/07/001860
Enrollment
80
Registered
2011-07-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hepatorenal syndrome

Interventions

Intervention1: Terlipressin plus albumin: Terlipressin dose 0.5 mg 6 hourly plus albumin dose 20gm/day for 5 days. Route of administration: Intravenous Control Intervention1: Low dose dopamine, fruse

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with cirrhosis and HRS as defined by International ascites club diagnostic criteria

Exclusion criteria

Exclusion criteria: Active GI bleed, Presence of sepsis or hypotension requiring inotropic support, Known underlying pre-existing primary renal disease, Ischemic heart disease, Hepatocellular carcinoma, Diabetes mellitus, Portal vein thrombosis, HVOTO, Tubercular peritonitis, Lack of informed consent

Design outcomes

Primary

MeasureTime frame
1) Proportion of patients with improvement in urine output, serum creatinine and PRA by 50% 2) Survival among the two treatment regimesTimepoint: 1) day 5 and 15 between two treatment groups 2) day 7, 14, 4 weeks, 12 weeks, 24 weeks—

Secondary

MeasureTime frame
1)Recurrence of HRS requiring hospitalization 2) Side effect of therapy 3) Cost of therapyTimepoint: 1) 6 months—

Countries

India

Contacts

Public ContactS K Acharya
subratacharya2004@yahoo.com01126594934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 15, 2026